About ForteBio
ForteBio is a Healthcare company based in Menlo Park (United States) founded in 2001, and was acquired by Pall in December 2011. Real-time biomolecular interactions are analyzed using specialized instruments. ForteBio has raised $42.3 million across 2 funding rounds from investors including Orbimed, Pall and Turmeric Acquisition Corp. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Biosensors.
Company details
ForteBio develops instruments for the real-time analysis of biomolecular interactions based on the companys proprietary Bio-Layer Interferometry (BLI) techology - a label-free optical analysis method that measures biomolecular interactions by the changes in the interference pattern of white light reflected from two surfaces (a layer of immobilized protein on the biosensor tip, and an internal reference layer) due to changes in the number of molecules binding to the biosensor tip. The change in interference pattern can be measured in real time. Since only the molecules binding to the biosensor tip contribute to the change in interference patterns, and hence the signal, the system can be used to generate highly specific data from complex mixtures. The company has four main product lines. The Octet range is the all-inclusive instrumentation, reagent and assay-integrated system that enables the study of protein-protein interactions in 96 and 384 well plates. The Blitz product range enables label-free cell analysis for single researchers and standalone labs. In addition, it also manufactures the Dip and Read biosensors and assays, and the Ready BLI assay range. In Dec 2011, Pall acquired ForteBio for an undisclosed sum.
- Headquarters Menlo Park, United States
- Stage Acquired
- SectorsHealthcare
- Website fortebio.com
- Social LinkedIn X
- Acquired by Pall (Dec 2011)
Funding Insights of ForteBio
ForteBio has successfully raised a total of $42.3M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $25 million completed in September 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.3M
- Total Rounds 2
- Last Round Series C — $25M
- First Round $17.3M
(Oct 2005)
- Investors Count 6
All 2 funding rounds of ForteBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2008 | $25M | Series C | – | – | |
| Oct 2005 | $17.3M | Series B | – | – |
7 investors in total: 7 institutional.
Investors in ForteBio
ForteBio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Pall and Turmeric Acquisition Corp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early stage venture capital firm investing in the US | alloyventures.com | Palo Alto, United States | ||
Early-stage healthcare startups are supported with venture capital. | lvpcapital.com | San Ramon, United States | ||
Investments in early and late-stage US companies are made. | vertical-group.com | Basking Ridge, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Filtration, separation, and purification solutions are provided for various industries. | 1946 | pall.com | New York, United States |
Investor details for ForteBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ForteBio
4 dated milestones of ForteBio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded ForteBio is founded.
- Funding First funding round of $17.3M.
- Funding Latest funding round, Series C, of $25.0M.
- Exit Acquired by Pall.
Web traffic of ForteBio
Websites that share an audience with ForteBio (fortebio.com).
Websites whose visitors overlap most with ForteBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biacore.com | 100% | View details | |||
| healthtech.com | 82% | #1,688,467 | View details | ||
tdi.ox.ac.uk | tdi.ox.ac.uk | 77% | – | ||
sibcb.ac.cn | sibcb.ac.cn | 75% | #1,984,742 | – | |
| metabion.com | 74% | #3,974,909 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for ForteBio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as ForteBio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fortebio
Complete news archive for ForteBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ForteBio
ForteBio was founded in 2001 and raised its 1st funding round 4 years after it was founded.
ForteBio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
ForteBio is a funded company, having raised a total of $42.3M across 2 funding rounds to date. The company's 1st funding round was a Series B of $17.3M, raised on Oct 2005.
ForteBio develops instruments for the real-time analysis of biomolecular interactions based on the companys proprietary Bio-Layer Interferometry (BLI) techology - a label-free optical analysis method that measures biomolecular interactions by the changes in the interference pattern of white light reflected from two surfaces (a layer of immobilized protein on the biosensor tip, and an internal reference layer) due to changes in the number of molecules binding to the biosensor tip. The change in interference pattern can be measured in real time. Since only the molecules binding to the biosensor tip contribute to the change in interference patterns, and hence the signal, the system can be used to generate highly specific data from complex mixtures. The company has four main product lines. The Octet range is the all-inclusive instrumentation, reagent and assay-integrated system that enables the study of protein-protein interactions in 96 and 384 well plates. The Blitz product range enables label-free cell analysis for single researchers and standalone labs. In addition, it also manufactures the Dip and Read biosensors and assays, and the Ready BLI assay range. In Dec 2011, Pall acquired ForteBio for an undisclosed sum.
ForteBio has 7 investors. Key investors include Orbimed, Pall, Turmeric Acquisition Corp, Alloy Ventures, and Latterell Venture Partners.
Yes. ForteBio was acquired by Pall in December 2011.